Prenetics Global (NASDAQ:PRE - Get Free Report) had its price objective lowered by stock analysts at B. Riley Financial from $37.00 to $31.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. B. Riley Financial's target price points to a potential upside of 192.18% from the company's previous close.
Several other brokerages also recently weighed in on PRE. Maxim Group began coverage on shares of Prenetics Global in a research note on Monday, October 26th. They issued a "buy" rating and a $41.00 target price for the company. Craig Hallum initiated coverage on shares of Prenetics Global in a research note on Thursday, September 17th. They set a "buy" rating and a $40.00 price target on the stock. Wall Street Zen upgraded shares of Prenetics Global from a "sell" rating to a "hold" rating in a report on Saturday, August 22nd. Lucid Cap Mkts upgraded shares of Prenetics Global to a "strong-buy" rating in a report on Monday, October 12th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Prenetics Global in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, Prenetics Global presently has an average rating of "Moderate Buy" and an average price target of $36.17.
View Our Latest Stock Analysis on Prenetics Global
Prenetics Global Price Performance
Prenetics Global stock traded up $0.26 during midday trading on Thursday, hitting $10.61. 373,013 shares of the company were exchanged, compared to its average volume of 232,161. The company's fifty day moving average price is $19.80 and its 200-day moving average price is $19.48. The company has a market cap of $179.03 million, a PE ratio of -2.50 and a beta of 0.40. Prenetics Global has a fifty-two week low of $9.13 and a fifty-two week high of $27.24.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings data on Sunday, November 1st. The company reported ($1.45) earnings per share (EPS) for the quarter. The firm had revenue of $64.11 million during the quarter. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. On average, analysts expect that Prenetics Global will post -2.36 EPS for the current fiscal year.
Insider Activity at Prenetics Global
In other Prenetics Global news, CEO Danny Sheng Wu Yeung bought 17,181 shares of the business's stock in a transaction on Monday, August 24th. The shares were bought at an average cost of $21.23 per share, with a total value of $364,752.63. Following the transaction, the chief executive officer directly owned 112,416 shares in the company, valued at approximately $2,386,591.68. This trade represents a 18.04% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Brian Rosin bought 5,100 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was acquired at an average cost of $22.80 per share, for a total transaction of $116,280.00. Following the completion of the transaction, the chief financial officer owned 23,100 shares in the company, valued at $526,680. This represents a 28.33% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 40,281 shares of company stock worth $862,453 over the last 90 days. 7.80% of the stock is owned by company insiders.
Hedge Funds Weigh In On Prenetics Global
Hedge funds have recently bought and sold shares of the company. Prospect Capital Advisors LLC bought a new stake in shares of Prenetics Global in the 3rd quarter valued at approximately $9,279,000. Pillsbury Lake Capital LLC acquired a new position in Prenetics Global in the third quarter valued at approximately $4,407,000. Marshall Wace LLP bought a new position in Prenetics Global during the 3rd quarter worth $3,643,000. Renaissance Technologies LLC increased its position in Prenetics Global by 85.1% in the first quarter. Renaissance Technologies LLC now owns 31,322 shares of the company's stock worth $605,000 after buying an additional 14,400 shares during the period. Finally, Stevens Capital Partners lifted its stake in Prenetics Global by 9.0% in the third quarter. Stevens Capital Partners now owns 30,674 shares of the company's stock valued at $709,000 after buying an additional 2,527 shares during the last quarter. 25.01% of the stock is currently owned by institutional investors and hedge funds.
Top Prenetics Global Stories
Here are a few of the latest stories about PRE:
- Positive Sentiment: Q3 revenue rose about 228% year over year to $64.1 million, beating both company guidance and analyst estimates. IM8 revenue increased 266% to $62.9 million, its seventh consecutive record quarter. Prenetics reaffirmed 2026 revenue guidance of $220–230 million and forecast IM8 revenue of more than $400 million in 2027. Prenetics Q3 results and guidance
- Positive Sentiment: Management reported a $4.1 million positive adjusted free cash flow and said IM8’s earliest customer cohort generated gross profit of about 4.1 times its acquisition cost. Prenetics Q3 results and guidance
- Neutral Sentiment: Q4 revenue guidance of $73–83 million brackets the $78.6 million analyst consensus, offering no clear near-term sales surprise. Prenetics shares down on wider loss and lowered second-half guidance
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.